{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T22:48:08Z","timestamp":1773442088979,"version":"3.50.1"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,3,3]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Evaluate the effect of upadacitinib on pain outcomes in patients with active psoriatic arthritis (PsA) or ankylosing spondylitis (AS) across 3 randomised trials (SELECT-PsA 1 and 2 for PsA; SELECT-AXIS 1 for AS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients were randomised to upadacitinib 15 mg once daily or placebo (all 3 studies), or adalimumab 40 mg every other week (SELECT-PsA 1 only). Pain outcomes included proportion of patients achieving \u226530%, \u226550% and \u226570% reduction from baseline in patient global assessment of pain and other end points.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A higher proportion of patients receiving upadacitinib versus placebo achieved \u226530%, \u226550% and \u226570% reduction in pain end points as early as week 2; these improvements with upadacitinib were generally sustained or increased through year 1 (PsA 1\/2 studies: 64%\/48%, 58%\/42% and 38%\/22%, respectively; SELECT-AXIS 1 study: 76%, 72% and 54%). Results were similar with adalimumab in PsA 1 (59%, 49% and 32%). Patients who switched from placebo to upadacitinib 15 mg were able to reach a similar level of improvement as the continuous upadacitinib groups by year 1 (PsA 1\/2 studies: 46%\u201360%, 35%\u201349% and 15%\u201334%; AS study: 83%, 72% and 46%). Results were similar with other pain end points.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Rapid and sustained improvements in pain outcomes across several end points were consistently shown with upadacitinib over 1 year in patients with active PsA or AS who had either inadequate response to prior non-biologic or biologic disease-modifying antirheumatic drugs (PsA studies) or were biologic-na\u00efve with inadequate response to non-steroidal anti-inflammatory drugs (AS study).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-002049","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T05:52:57Z","timestamp":1666590777000},"page":"e002049","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct03104400","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03104374","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03178487","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04169373","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-4280","authenticated-orcid":false,"given":"Iain B","family":"McInnes","sequence":"first","affiliation":[{"name":"University of Glasgow, College of Medical, Veterinary and Life Sciences, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-4827","authenticated-orcid":false,"given":"Andrew J K","family":"Ostor","sequence":"additional","affiliation":[{"name":"Department of Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Rheumatolgy, Cabrini Medical Centre, Malvern, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Swedish Medical Center, Providence St Joseph Health, and School of Medicine, University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Tillett","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Royal National Hospital for Rheumatic Disease, Bath, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"de Vlam","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[{"name":"Department of Medicine, Laval University, Quebec City, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Lippe","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH and Co KG, Wiesbaden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Maniccia","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Feng","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianming","family":"Gao","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Zueger","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Saffore","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Ho","family":"Song","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"2025090313124317000_8.1.e002049.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60071-8"},{"key":"2025090313124317000_8.1.e002049.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2025090313124317000_8.1.e002049.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2025090313124317000_8.1.e002049.4","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the American College of Rheumatology\/Spondylitis association of America\/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and Nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313124317000_8.1.e002049.5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313124317000_8.1.e002049.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2025090313124317000_8.1.e002049.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7"},{"key":"2025090313124317000_8.1.e002049.8","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1136\/annrheumdis-2018-213334","article-title":"Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis","volume":"77","author":"Yap","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025090313124317000_8.1.e002049.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31591-4"},{"key":"2025090313124317000_8.1.e002049.10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13075-018-1565-4","article-title":"Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study","volume":"20","author":"Haroon","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025090313124317000_8.1.e002049.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171094"},{"key":"2025090313124317000_8.1.e002049.12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s40744-020-00234-3","article-title":"Evaluating inflammatory versus mechanical back pain in individuals with psoriatic arthritis: a review of the literature","volume":"7","author":"Grinnell-Merrick","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2025090313124317000_8.1.e002049.13","doi-asserted-by":"publisher","DOI":"10.1177\/0300060513488501"},{"key":"2025090313124317000_8.1.e002049.14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13075-017-1333-x","article-title":"Work outcome in yet undiagnosed patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis; results of a cross-sectional study among patients with chronic low back pain","volume":"19","author":"van Hoeven","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090313124317000_8.1.e002049.15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2025090313124317000_8.1.e002049.16","first-page":"CD008886","article-title":"Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis)","volume":"10","author":"Ramiro","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090313124317000_8.1.e002049.17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40271-017-0221-4","article-title":"Important treatment outcomes for patients with psoriatic arthritis: a multisite qualitative study","volume":"10","author":"Dures","year":"2017","journal-title":"Patient"},{"key":"2025090313124317000_8.1.e002049.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key070"},{"key":"2025090313124317000_8.1.e002049.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210322"},{"key":"2025090313124317000_8.1.e002049.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32463-2"},{"key":"2025090313124317000_8.1.e002049.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"2025090313124317000_8.1.e002049.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"2025090313124317000_8.1.e002049.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219601"},{"key":"2025090313124317000_8.1.e002049.24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2025090313124317000_8.1.e002049.25","first-page":"312","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025090313124317000_8.1.e002049.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"2025090313124317000_8.1.e002049.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6"},{"key":"2025090313124317000_8.1.e002049.28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/art.41911","article-title":"Upadacitinib in active ankylosing spondylitis: 1-year results from the double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension","volume":"74","author":"Deodhar","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025090313124317000_8.1.e002049.29","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-eular.1346","article-title":"Baricitinib showed rapid and greater reduction in pain compared to adalimumab or placebo in patients with rheumatoid arthritis","volume":"76","author":"Taylor","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025090313124317000_8.1.e002049.30","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001131"},{"key":"2025090313124317000_8.1.e002049.31","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8091394","article-title":"Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM","volume":"8","author":"Fautrel","year":"2019","journal-title":"J Clin Med"},{"key":"2025090313124317000_8.1.e002049.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209821"},{"key":"2025090313124317000_8.1.e002049.33","unstructured":"RINVOQ\u2122 . (upadacitinib) prescribing information. North Chicago, IL: AbbVie Inc., 2020."},{"key":"2025090313124317000_8.1.e002049.34","unstructured":"RINVOQ . upadacitinib: AbbVie Deutschland GmbH & Co. KG, 2019."},{"key":"2025090313124317000_8.1.e002049.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2003.09.004"},{"key":"2025090313124317000_8.1.e002049.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.09.005"},{"key":"2025090313124317000_8.1.e002049.37","first-page":"abst 1372","article-title":"Efficacy and safety of upadacitinib in patients with psoriatic arthritis and axial involvement [abstract]","volume":"72","author":"Deodhar","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025090313124317000_8.1.e002049.38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40744-017-0066-2","article-title":"Improving the management of psoriatic arthritis and axial spondyloarthritis: roundtable discussions with healthcare professionals and patients","volume":"4","author":"Garrido-Cumbrera","year":"2017","journal-title":"Rheumatol Ther"},{"key":"2025090313124317000_8.1.e002049.39","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001240"},{"key":"2025090313124317000_8.1.e002049.40","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/msc.1513","article-title":"Ankylosing spondylitis and undifferentiated spondyloarthritis: the relationship between living with these diseases and psychological well-being","volume":"19","author":"Kelly","year":"2021","journal-title":"Musculoskeletal Care"},{"key":"2025090313124317000_8.1.e002049.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209463"},{"key":"2025090313124317000_8.1.e002049.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211315"},{"key":"2025090313124317000_8.1.e002049.43","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"},{"key":"2025090313124317000_8.1.e002049.44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13075-018-1610-3","article-title":"Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study","volume":"20","author":"McInnes","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025090313124317000_8.1.e002049.45","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092767"},{"key":"2025090313124317000_8.1.e002049.46","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-016-0581-0"},{"key":"2025090313124317000_8.1.e002049.47","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8564215","article-title":"Chronic pain in inflammatory arthritis: mechanisms, metrology, and emerging targets-a focus on the JAK-STAT pathway","volume":"2018","author":"Salaffi","year":"2018","journal-title":"Pain Res Manag"},{"key":"2025090313124317000_8.1.e002049.48","doi-asserted-by":"crossref","first-page":"668","DOI":"10.55563\/clinexprheumatol\/e7ayu8","article-title":"Jak\/Stat pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis","volume":"39","author":"Crispino","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313124317000_8.1.e002049.49","first-page":"abstr 2524","article-title":"Effect of upadacitinib on pain and morning stiffness in patients with rheumatoid arthritis and inadequate response to conventional synthetic or biologic disease-modifying anti-rheumatic drugs [abstract]","volume":"70","author":"Wells","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090313124317000_8.1.e002049.50","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-002049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:12:55Z","timestamp":1756930375000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-002049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3,24]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/rmdopen-2021-002049"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-002049","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}